Hyperbilirubinemia After Cardiac Surgery

Hyperbilirubinemia After Major Cardiac or Thoracic Aorta Surgery: Predictors and Clinical Significance

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01617902

Enrollment

1000

Registered

2012-06-13

Start date

2012-06-30

Completion date

2013-08-31

Last updated

2012-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases

Keywords

Hyperbilirubinemia, cardiac, surgery, aorta, prognosis

Brief summary

This study aims to evaluate the incidence and risk factors of hyperbilirubinemia following major cardiac or thoracic aorta surgery, and to determine the clinical impacts of the hyperbilirubinemia on postoperative mortality and morbidity.

Detailed description

Patients receiving elective cardiac or thoracic aorta surgery will be monitored for the development of postoperative hyperbilirubinemia. Collection of data will include patient baseline demographic characteristics, laboratory and echocardiographic findings, procedural factors of the surgery, and early postoperative variables. Serial postoperative liver function testings will be done during the hospitalization. Postoperative hyperbilirubinemia is defined as serum bilirubin level of 3mg/dL.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients aged over 18 years who are scheduled to undergo elective major cardiac or thoracic aorta surgery. Major cardiac surgery includes coronary artery bypass grafting, pericardiectomy and corrections of cardiac diseases using cardiopulmonary bypassing (valve surgery, tumor excision, arrhythmia surgery, heart transplantation, ventricular reconstruction, pulmonary thromboembolectomy, and atrial or ventricular septal defects closure).

Exclusion criteria

1. univentricular or one-and-half ventricle repairs 2. presence of known liver cirrhosis or hepatic cancer 3. history of liver transplantation 4. Genetic diseases that affects bilirubin metabolism (i.e. Gilbert syndrome) 5. preoperative bilirubin level of 3mg/dL or more.

Design outcomes

Primary

Measure	Time frame
All cause-death	Within 30 days after surgery or during postoperative hospitalization

Secondary

Measure	Time frame
gastrointestinal or hepatobiliary complications requiring intervention	Within 30 days after surgery or during postoperative hospitalization

Countries

South Korea

Contacts

Primary ContactJoon Bum Kim, MD

jbkim1975@amc.seoul.kr82-2-3010-5416

Outcome results